Trillium Asset Management LLC decreased its position in shares of Hologic Inc. (NASDAQ:HOLX) by 0.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 495,233 shares of the company’s stock after selling 3,242 shares during the period. Hologic accounts for about 1.1% of Trillium Asset Management LLC’s investment portfolio, making the stock its 24th largest position. Trillium Asset Management LLC’s holdings in Hologic were worth $17,135,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in HOLX. Cleararc Capital Inc. bought a new position in Hologic during the first quarter valued at approximately $213,000. Acrospire Investment Management LLC bought a new position in Hologic during the first quarter valued at approximately $293,000. ING Groep NV bought a new position in Hologic during the second quarter valued at approximately $295,000. QUANTRES ASSET MANAGEMENT Ltd bought a new position in Hologic during the second quarter valued at approximately $391,000. Finally, BlueMountain Capital Management LLC bought a new position in Hologic during the first quarter valued at approximately $464,000. Institutional investors and hedge funds own 94.51% of the company’s stock.
Shares of Hologic Inc. (NASDAQ:HOLX) traded up 0.69% on Tuesday, reaching $39.15. 3,612,008 shares of the company traded hands. The stock has a market capitalization of $10.86 billion, a price-to-earnings ratio of 43.16 and a beta of 1.00. Hologic Inc. has a 1-year low of $31.84 and a 1-year high of $41.66. The company has a 50-day moving average of $38.33 and a 200-day moving average of $36.10.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, July 27th. The company reported $0.51 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.48 by $0.03. The business earned $717.40 million during the quarter, compared to analysts’ expectations of $703.66 million. Hologic had a net margin of 9.39% and a return on equity of 26.25%. The business’s quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter last year, the company posted $0.43 earnings per share. Analysts anticipate that Hologic Inc. will post $1.94 earnings per share for the current fiscal year.
Several analysts recently issued reports on HOLX shares. Leerink Swann reissued an “outperform” rating and issued a $46.00 target price on shares of Hologic in a research note on Monday. Zacks Investment Research raised Hologic from a “hold” rating to a “buy” rating and set a $43.00 target price on the stock in a research note on Wednesday, September 28th. Barclays PLC raised Hologic from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $42.00 to $44.00 in a research note on Friday, September 23rd. Piper Jaffray Cos. set a $44.00 target price on Hologic and gave the stock a “hold” rating in a research note on Sunday, August 28th. Finally, RBC Capital Markets reissued a “sector perform” rating and issued a $39.00 target price (up from $37.00) on shares of Hologic in a research note on Monday, August 1st. Six research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $42.71.
In other Hologic news, Director Nancy Leaming sold 8,179 shares of the firm’s stock in a transaction on Thursday, July 21st. The shares were sold at an average price of $37.00, for a total value of $302,623.00. Following the completion of the transaction, the director now owns 67,140 shares of the company’s stock, valued at $2,484,180. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.84% of the stock is currently owned by company insiders.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.